Researchers unveiled a promising new treatment for advanced pancreatic cancer that aims to improve survival rates. The new oral medication, called daraxonrasib, has sparked hope by increasing life expectancy for patients battling this aggressive cancer.
Significant Advances in Treatment
Dr. Zev Wainberg from the University of California, Los Angeles, emphasized the drug represents a significant progression, although it does not cure the cancer. Daraxonrasib targets a mutated protein that promotes tumor growth in over 90% of pancreatic cancer cases, an elusive target for years.
Study Results
In a recent study, 500 patients with metastatic pancreatic cancer, resistant to previous treatments, were randomly assigned this drug or additional chemotherapy. Daraxonrasib nearly doubled patient survival times with fewer severe side effects compared to traditional methods. Patients treated with the pill lived a median of 13.2 months, compared to 6.7 months for those on chemotherapy. This marks the first substantial drug success over chemotherapy, published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago.
Patient Experience
Dr. Rachna Shroff of the University of Arizona Cancer Center expressed her emotion at the ASCO meeting, noting the drug offered real benefits and improved quality of life, as patients experienced less pain with shrinking tumors. Many continued using the drug well beyond the study’s end.
Future Implications
“A new standard of care,” Dr. Brian Wolpin from the Dana-Farber Cancer Institute called the pill’s potential role in therapeutic strategies for metastatic pancreatic cancer.
Research will further explore its application at earlier disease stages and assess whether tumor shrinkage enhances surgical qualification rates for patients.
Side Effects and Approval
Common side effects that might influence usage include severe rashes and mouth sores. Revolution Medicines, the company behind the development, funded the research. The FDA plans an expedited review, currently allowing “expanded access” for patients meeting specific criteria. Former U.S. Sen. Ben Sasse highlighted its effectiveness on “60 Minutes,” increasing public interest.
Challenges in Pancreatic Cancer
The American Cancer Society projects about 67,000 new U.S. cases this year, with over 52,000 fatalities due to late detection. Pancreatic cancer’s five-year survival rate is 13%, struggling for viable alternatives to chemotherapy compared to other cancers.
Scientific Breakthrough
Daraxonrasib targets KRAS gene mutations, frequent in pancreatic cancer and once deemed undruggable due to structural challenges inhibiting drug interaction. This medication uses molecular glue to bind KRAS subtypes, with future research potentially identifying subtype-specific effectiveness.
Dr. Andrew Coveler from the Fred Hutchinson Cancer Center noted the drug’s distinct functionality, acknowledging ongoing development of other targeted therapies and vaccine approaches.
The Associated Press recognizes funding support from the Howard Hughes Medical Institute and the Robert Wood Johnson Foundation but maintains sole responsibility for content.